Metformin Therapy in Type 1 Diabetes Mellitus.

• Conditions: Loss of Control of Diabetes

• Registration Number: NCT01889706
• Lead Sponsor: Poznan University of Medical Sciences

Brief Summary

The use of exogenous insulin and incorrect nutritional habits are conducive to obesity and excess weight. This leads to the development of insulin resistance, even in patients with type 1 diabetes mellitus. The purpose of this study is to assess the effects of metformin as adjunctive therapy on anthropometric parameters, insulin resistance and metabolic control in overweight and obese patients with type 1 diabetes mellitus.

The study group consists of 200 Caucasian type 1 diabetic patients with elevated adipose tissue content as measured by electrical bioimpedance, treated at the Poznan University of Medical Sciences Department of Diabetology in 2009-2014. All patients have type 1 diabetes diagnosed by autoimmune antibodies, and are treated with intensive insulin therapy. This group is divided into metformin treated arm (group I+ M, 100 subjects), the remaining 100 patients are treated with insulin alone (control group, group I). Metformin is administered at least 6 months at a mean dose of 1000 mg/day.

The investigators would like to assess the impact of metformin treatment on metabolic control, insulin resistance and anthropometric parameters in overweight and obese patients with type 1 diabetes.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2013-03
• Status Verified: 2013-06
• Study First Submitted: 2013-06-25
• Study First Submitted QC: 2013-06-26
• Last Update Submitted: 2013-06-26
• Study First Posted: 2013-06-28
• Last Update Posted: 2013-06-28
• Study Completion: 2014-02

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• age > 18 years <60 years,
• duration of diabetes >3 years,
• lack of metabolic control- HbA1C>7,5% (despite participation in 5-day WHO education program)
• treated with intensive insulin therapy

Exclusion Criteria

• metabolically decompensate diabetes with acetonuria,
• suspected lack of compliance,
• lack of glucose and ketones self-monitoring,
• hypoglycaemic unawareness or recurrent severe hypoglycemia (defined as more than two episodes of hypoglycemia lowered than 60 mg/dl with loss of consciousness, required assistance to treat) in the past 3 months,
• recurrent diabetic ketoacidosis (more than two episodes in the past year)
• another serious medical illness,
• pregnancy or sexually active woman unwilling to take birth control.
• renal impairment (estimated on the value calculated glomerular filtration rate using the MDRD formula-estimated glomerular filtration rate, eGFR<45 mL / min
• liver cell damage Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) greater than twice the upper normal limit),
• history of drug or alcohol abuse or those who used this drug before
• changes in the way of antihypertensive and antihyperlipemic treatment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Body fat content and anthropometric parameters	6 months	assessed by electrical bioimpedance using a Tanita BC-418 MA device,

Secondary Outcome Measures

Name	Time	Method
Assessment of metabolic control	6 months	(HbA1C, lipid profile)
Insulin requirement	3 , 6 months

Trial Locations

Locations (1)

Department of Internal Medicine and Diabetology, Raszeja Hospital; 🇵🇱 Poznan, Great Poland, Poland